| Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis (NCT04130919) | Gilead Sciences | 2019-12-20 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy (NCT04115748) | Gilead Sciences | 2019-12-03 |
| Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV (NCT04143594) | Gilead Sciences | 2019-11-22 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy (NCT04115839) | Gilead Sciences | 2019-11-13 |
| A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC (NCT04024813) | Gilead Sciences | 2019-11-12 |
| Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis (NCT04060147) | Gilead Sciences | 2019-10-17 |
| Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis (NCT04112303) | Gilead Sciences | 2019-10-16 |
| Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors (NCT03964727) | Gilead Sciences | 2019-10-15 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors (NCT04049617) | Gilead Sciences | 2019-08-26 |
| Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) (NCT03987074) | Gilead Sciences | 2019-07-29 |
| Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease (NCT04026165) | Gilead Sciences | 2019-07-24 |
| Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) (NCT04009057) | Gilead Sciences | 2019-07-09 |
| Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters (NCT03960645) | Gilead Sciences | 2019-06-28 |
| Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors (NCT03954704) | Gilead Sciences | 2019-06-03 |
| Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents (NCT03349346) | Gilead Sciences | 2019-06-01 |
| Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) (NCT03852433) | Gilead Sciences | 2019-05-31 |
| Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer (NCT03901339) | Gilead Sciences | 2019-05-08 |
| Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers (NCT03912831) | Gilead Sciences | 2019-04-30 |
| Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD) (NCT03852719) | Gilead Sciences | 2019-04-17 |
| Study of Cilofexor in Adults With Primary Sclerosing Cholangitis (NCT03890120) | Gilead Sciences | 2019-03-27 |
| Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection (NCT03820258) | Gilead Sciences | 2019-01-28 |
| Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (NCT03580668) | Gilead Sciences | 2018-11-13 |
| ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) (NCT03602560) | Gilead Sciences | 2018-10-01 |
| Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland (NCT03582098) | Gilead Sciences | 2018-09-12 |
| Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment (NCT03615066) | Gilead Sciences | 2018-08-28 |
| Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (NCT03631732) | Gilead Sciences | 2018-08-28 |
| Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread (NCT03547973) | Gilead Sciences | 2018-08-13 |
| Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma (NCT03568929) | Gilead Sciences | 2018-05-25 |
| A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH) (NCT03551522) | Gilead Sciences | 2018-04-30 |
| Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B (NCT03491553) | Gilead Sciences | 2018-04-06 |
| Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function (NCT03417778) | Gilead Sciences | 2018-04-03 |
| Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus (NCT03472326) | Gilead Sciences | 2018-04-03 |
| Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (NCT03449446) | Gilead Sciences | 2018-03-21 |
| Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years (NCT03405935) | Gilead Sciences | 2018-03-01 |
| Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB) (NCT03434353) | Gilead Sciences | 2018-02-28 |
| Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC) (NCT03301506) | Gilead Sciences | 2017-12-12 |
| Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria (NCT03219164) | Gilead Sciences | 2017-11-28 |
| Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects (NCT03369002) | Gilead Sciences | 2017-11-27 |
| Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) (NCT02574455) | Gilead Sciences | 2017-11-07 |
| Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN) (NCT03285711) | Gilead Sciences | 2017-10-06 |
| Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies (NCT03248479) | Gilead Sciences | 2017-09-08 |